Key Points
- Isomorphic Labs closed a $5 billion Series C, calling the round oversubscribed.
- Greenoaks and Sequoia co-led; Alphabet, a16z, MGX and Temasek also invested.
- Money funds a push from preclinical results into human trials.
The latest:
Isomorphic Labs said on November 17, 2026 that it had closed a $5 billion Series C round, describing it as oversubscribed, in one of the largest financings yet for an artificial-intelligence drug design company. The London-based firm, founded in 2021 and led by Demis Hassabis, said the capital will carry its internal and partnered drug candidates toward clinical trials. The company did not disclose a valuation.
Details:
- The round: Greenoaks and Sequoia Capital co-led the Series C, according to the company’s statement issued through PR Newswire. Andreessen Horowitz joined as a new investor, while Alphabet continued to back the firm. Existing investors participating included Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
- The Gulf stake: Abu Dhabi’s MGX is listed among existing investors taking part again, placing an Emirati state-linked fund alongside Alphabet and Singapore’s Temasek in a company positioning itself at the intersection of frontier AI and pharmaceutical development.
- Where the money goes: Isomorphic said it will develop and scale IsoDDE, its drug design engine built on foundational simulation models, and push its pipeline of wholly owned and partnered candidates into clinical studies. It also plans to expand into new biological areas using more advanced models.
- Infrastructure plans: The company said proceeds will fund a global AI-led bioengineering infrastructure and an AI-first translational and clinical development capability, alongside a partner ecosystem for studying the mechanistic biology of disease. No timeline was given for when that infrastructure would be operational.
- The pipeline: Isomorphic describes a multi-modality pipeline of AI-designed therapeutic candidates and says it has achieved positive preclinical results across internal oncology and immunology programs as well as partnered programs, which it presents as the basis for moving into the clinical stage.
- The leadership: Hassabis, the DeepMind chief who co-founded Isomorphic in 2021, serves as founder and chief executive, with Max Jaderberg as president. The firm is headquartered in London with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
- The pitch: Hassabis said the company’s drug design engine is generating molecules with unprecedented precision and speed. Jaderberg said the firm is making repeatable scientific advances each week enabled by its models. Neither executive named a specific candidate or disease target scheduled to enter trials first.
- The investor case: Neil Mehta, founder and managing partner at Greenoaks, framed drug discovery as an optimization challenge of nearly infinite scale. Konstantine Buhler, a partner at Sequoia Capital, said Isomorphic is building foundational technology for the future of medicine.
Background:
Isomorphic was spun out of Alphabet’s DeepMind in 2021 to apply protein-structure prediction methods to drug design. It operates through a mix of wholly owned programs and partnerships with pharmaceutical companies, a model that shares development risk while retaining upside on internal candidates.
Between the lines:
The round’s framing points to a transition rather than a discovery milestone. The stated uses of funds — clinical development infrastructure, translational capability, a push toward trials — describe the expensive, slow part of pharmaceuticals that AI has not yet compressed. Preclinical results in oncology and immunology are the company’s evidence base so far; human trials are where that evidence gets tested.
What’s next
Watch for Isomorphic to name its first candidate entering clinical trials and the disease target, plus any disclosure of valuation, trial timelines, or new pharmaceutical partnerships beyond its existing collaborations.